NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 137 filers reported holding NEKTAR THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 5.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $293,020 | -19.7% | 491,975 | -22.5% | 0.00% | 0.0% |
| Q2 2023 | $365,058 | +15.9% | 634,663 | +41.6% | 0.00% | 0.0% |
| Q1 2023 | $315,059 | -13.6% | 448,227 | +177.8% | 0.00% | 0.0% |
| Q4 2022 | $364,599 | +972.4% | 161,327 | +1406.5% | 0.00% | – |
| Q3 2022 | $34,000 | -76.4% | 10,709 | -71.7% | 0.00% | -100.0% |
| Q2 2022 | $144,000 | -84.1% | 37,837 | -77.5% | 0.00% | -75.0% |
| Q1 2022 | $908,000 | +26.6% | 168,477 | +217.3% | 0.00% | 0.0% |
| Q4 2021 | $717,000 | +165.6% | 53,102 | +237.5% | 0.00% | +300.0% |
| Q2 2021 | $270,000 | -51.3% | 15,736 | -38.7% | 0.00% | -75.0% |
| Q4 2019 | $554,000 | +224.0% | 25,675 | +100.6% | 0.00% | +300.0% |
| Q1 2014 | $171,000 | – | 12,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |